 Heartflow Holding Inc NYSE: HFLO aims to bring its noninvasive, artificial intelligence AI-based test for coronary heart disease to more doctors and patients via a SPAC merger with Longview Acquisition Corp II NYSE: LGV. Once the deal, valued at an enterprise value of about 2.4 billion, is complete, the resulting public company will operate under HeartFlows banner with the NYSE ticker HFLO. 